RQM+ Appoints Denise Wocko as Head of Global Client Portfolio Management
RQM+, the world’s leading MedTech service provider, today announced the appointment of Denise Wocko as head of global client portfolio management. In her new role, Wocko will work directly with RQM+ clients to provide seamless access to its integrated services, including reimbursement, clinical trials, lab testing and regulatory consulting, that support all phases of the product lifecycle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230406005546/en/
Denise Wocko, RQM+ Head of Global Client Portfolio Management (Photo: Business Wire)
“We have an incredible opportunity to reduce the risk of clients who have trusted us with managing their regulatory and quality processes for 40 years by helping them navigate each critical step of their product’s journey,” said Wocko. “Our deep expertise in global regulatory consulting – with the largest global team of regulatory experts and former FDA, MHRA and notified body professionals – differentiates us and serves as the foundation for our expanded services. Our clients have asked us to integrate regulatory, clinical, biocompatibility and market access disciplines to give them efficient, end-to-end support. My goal is to make RQM+ the MedTech partner of choice by removing the challenges of a fragmented service landscape that manufacturers are dealing with today.”
Based in Geneva, Wocko has held commercial leadership roles at both niche and large organizations where she worked closely with clients to develop strategic partnerships that meet their objectives. Her experience spans the MedTech, pharmaceutical and biotech industries, as well as with the contract research organizations (CROs) that serve them.
RQM+ is the leading MedTech service provider with the world’s largest global team of regulatory and quality experts. Building upon 40 years of regulatory expertise, we also provide comprehensive clinical trial, lab and reimbursement services – reducing risk throughout the entire product lifecycle for medical devices, digital therapeutics and diagnostics. With more former FDA, MHRA and notified body regulators than any other firm, the RQM+ team has deep expertise in all clinical specialties. We currently works for 19 of the top 20 medical device manufacturers and seven of the top 10 IVD companies. For more information, visit RQMplus.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005546/en/
Media: Rob Pepper, +1.301.254.6100, email@example.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kioxia Commences Operation of Two New R&D Facilities1.6.2023 09:00:00 EEST | Press release
Kioxia Corporation today commenced operation of two new R&D facilities — the Flagship Building at the Yokohama Technology Campus and the Shin-Koyasu Technology Front — strengthening the company’s research and development capabilities in flash memory and solid-state drives (SSDs). Going forward, other R&D functions in Kanagawa Prefecture will be relocated to these new R&D hubs to improve research efficiency and promote further advancement in technological innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531006054/en/ Flagship Building at Yokohama Technology Campus (Photo: Business Wire) With the addition of the new Flagship Building, the Yokohama Technology Campus will almost double in size, allowing Kioxia to expand its capabilities in evaluating flash memory and SSD products, thereby enhancing overall product development and product quality. Equipped with environmentally-friendly facilities, the Flagship Buildi
Inotrem Announces Publication of Two Key Articles on Nangibotide Phase II Programs in Peer-reviewed Medical Journals1.6.2023 09:00:00 EEST | Press release
Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory conditions, announced today the publication of the results of two phase 2 clinical studies in the The Lancet Respiratory Medicine and in eClinicalMedicine. The first article presents the ASTONISH Phase 2b trial in septic shock patients and the second one the ESSENTIAL Phase 2 trial for the treatment of critically ill COVID-19 patients. Both studies reveal that the TREM-1 pathway plays a central role in major life-threatening immune dysregulations caused by severe infections, whether it is septic shock or severe forms of COVID-19. The findings presented further validate Inotrem’s innovative approach to treat inflammatory diseases by targeting TREM-1. The two studies suggest that nangibotide, which targets TREM-1, is pathogen agnostic and has the potential to treat those very severe inflammatory conditions caused by both viral and bacterial infections. Both studies highl
Axelspace Announces New Management Structure1.6.2023 08:00:00 EEST | Press release
Axelspace Corporation (Head Office: Chuo-ku, Tokyo; CEO: Yuya Nakamura), a pioneer in microsatellites, announces its new management structure as of June 1, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531006007/en/ New Management Team Members: Front Row, Left to Right: Atsushi Yasuoka (Head of AxelLiner Business Division), Yuya Nakamura (CEO) , Daigo Orihara (CFO), Tatsuhiko Fukasawa (Head of AxelGlobe Business Division). Back Row, Left to Right: Yusuke Nakanishi (CSSO), Ryuichi Kokubo (Co-CTO/Information Technology), Takashi Eishima (Co-CTO/Aerospace Engineering), Makiko Hamada (CHRO), Sasaki (CISO), Yoshihiro Ota (CSO) (Photo: Business Wire) Axelspace announcement URL https://www.axelspace.com/news/20230601/ Background of Transition to New Management Structure Since our establishment in 2008 by a team of three members, our company has built a solid reputation by engaging in the development, manufacturing, and op
Preventing the Effects of Climate Change: EliTerra®, a Technological Platform Dedicated to Biosolutions That Reduce the Water Needs of Field Crops1.6.2023 06:06:00 EEST | Press release
Elicit Plant announces the acceleration of its scientific developments and its product roadmap by presenting the one and only technological platform that offers biosolutions to help prevent climatic risks for field crops by reducing their water consumption by up to 20%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230530005298/en/ @elicitplant On the occasion of its participation in the ChangeNOW Summit, the event for solutions for the planet that takes place from May 25 to 27, 2023 in Paris, Elicit Plant unveils EliTerra®, its technological platform and associated products that allow crops to adapt to climate change, particularly to drought. This is a world first that will boost the marketing of new Elicit Plant BioSolutions with a favorable environmental profile, following on from the success of its first product, BEST-a, which enables corn to consume up to 20% less water. "This type of solution is particularly expected
IFF Completed Divestiture of Savory Solutions Business31.5.2023 23:15:00 EEST | Press release
IFF (NYSE:IFF) today announced that it has successfully completed the previously announced divestiture of its Savory Solutions business unit to PAI Partners (PAI), a leading global private equity firm with a strong focus on the food and consumer industry. Under PAI ownership, Savory Solutions Group has been rebranded to NovaTaste, a global leader in taste innovation with headquarters in Salzburg, Austria. “The sale of IFF’s Savory Solutions Group represents our continued efforts to optimize our portfolio as we focus on core businesses and strengthen our capital structure,” said Frank Clyburn, IFF CEO. “We remain steadfast in our commitment to further pursue portfolio optimization opportunities as we drive toward our deleverage target by the end of 2024. We’re grateful to our Savory Solutions colleagues, who have demonstrated their commitment to innovation, service and quality. We wish them the best in their new journey.” Cautionary Statement under the Private Securities Litigation Refo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom